Abstract
Organophosphate nerve agents are still considered as potential threats in both military and terrorism situations. They are potent irreversible inhibitors of acetylcholinesterase in central and also in peripheral compartment. Huperzine A (Hup A) is a reversible AChE inhibitor that crosses the blood-brain barrier. It is presently approved for human use or is in course of clinical trials for the treatment of Alzheimers disease. This compound has also been successfully tested for pretreatment of organophosphate poisoning. In this study Hup A was tested as a prophylaxis against two V-nerve agents (VX and Russian VX). According to the obtained results, Hup A was able to partially protect AChE in the blood, diaphragm and brain against inhibition caused by Russian VX and VX.
Keywords: Huperzine A, VX, Russian VX, Brain, Nerve agent, Acetylcholinesterase, Pretreatment
Letters in Drug Design & Discovery
Title: Pretreatment with Huperzine A Protects Acetylcholinesterase in the Rat Brain Against Inhibition by VX and Russian VX
Volume: 6 Issue: 8
Author(s): Jana Zdarova Karasova, Jiri Bajgar, Ladislav Novotny and Kamil Kuca
Affiliation:
Keywords: Huperzine A, VX, Russian VX, Brain, Nerve agent, Acetylcholinesterase, Pretreatment
Abstract: Organophosphate nerve agents are still considered as potential threats in both military and terrorism situations. They are potent irreversible inhibitors of acetylcholinesterase in central and also in peripheral compartment. Huperzine A (Hup A) is a reversible AChE inhibitor that crosses the blood-brain barrier. It is presently approved for human use or is in course of clinical trials for the treatment of Alzheimers disease. This compound has also been successfully tested for pretreatment of organophosphate poisoning. In this study Hup A was tested as a prophylaxis against two V-nerve agents (VX and Russian VX). According to the obtained results, Hup A was able to partially protect AChE in the blood, diaphragm and brain against inhibition caused by Russian VX and VX.
Export Options
About this article
Cite this article as:
Karasova Zdarova Jana, Bajgar Jiri, Novotny Ladislav and Kuca Kamil, Pretreatment with Huperzine A Protects Acetylcholinesterase in the Rat Brain Against Inhibition by VX and Russian VX, Letters in Drug Design & Discovery 2009; 6 (8) . https://dx.doi.org/10.2174/157018009789353419
DOI https://dx.doi.org/10.2174/157018009789353419 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism AMPA Receptor Potentiators for the Treatment of CNS Disorders
Current Drug Targets - CNS & Neurological Disorders Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers
Current Medicinal Chemistry Endocrine Orchestration of Cardiovascular, Gastrointestinal and Hypothalamic Control
Current Medicinal Chemistry Programmed Symptoms: Disparate Effects United by Purpose
Current Rheumatology Reviews Chemical Biology: Past, Present and Future
Current Chemical Biology Pathological Gambling in Parkinson’s Disease: An Update on Medical Management
Current Psychopharmacology Mitochondrial Diseases in Childhood
Current Molecular Medicine MMP-9, a Potential Target for Cerebral Ischemic Treatment
Current Neuropharmacology Serotonin as a Modulator of Immune Function: An Overview
Current Immunology Reviews (Discontinued) The Path from Anti Parkinson Drug Selegiline and Rasagiline to Multifunctional Neuroprotective Anti Alzheimer Drugs Ladostigil and M30
Current Alzheimer Research Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry The Concept of Dysregulated Signal Transduction and Gene Expression in the Pathophysiology of Mood Disorders
Current Psychiatry Reviews Secretoneurin: A New Player in Angiogenesis and Chemotaxis Linking Nerves, Blood Vessels and the Immune System
Current Protein & Peptide Science Astroglial Connexins as a Therapeutic Target for Alzheimer's Disease
Current Pharmaceutical Design Targeting the Microglial Signaling Pathways: New Insights in the Modulation of Neuropathic Pain
Current Medicinal Chemistry Mitochondrial Complex I Deficiency in Humans
Current Genomics The Recent Development of α<sub>7</sub> Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases
Current Pharmaceutical Design Are the Extracelluar Pathways a Conduit for the Delivery of Therapeutics to the Brain?
Current Pharmaceutical Design Early Cerebral Infarction Following Aneurysmal Subarachnoid Hemorrhage: Frequency, Risk Factors, Patterns, and Prognosis
Current Neurovascular Research